FDA adds cancer and diabetes medicines to VAT-exempt list

The FDA has added several cancer and diabetes medicines to its VAT-exempt list. This decision follows a review by representatives from the FDA, Department of Health, Department of Finance, and the Bureau of Internal Revenue. Newly exempted medicines include cancer treatments like Degarelix and Tremelimumab, as well as diabetes medications such as Sitagliptin and Linagliptin. Medicines for mental illness, including Clomipramine and Chlorpromazine, are also included. The FDA regularly updates the VAT-exempt list, which has seen multiple additions this year. In August, 15 medicines were added, following earlier exemptions in March and January.